查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715626

按藥物類別、給藥途徑、分銷和最終用戶分類的肺動脈高血壓市場—2025-2030 年全球預測

Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計肺動脈高血壓市場規模到 2024 年將達到 91.2 億美元，到 2025 年將達到 97.7 億美元，複合年成長率為 7.46%，到 ​​2030 年將達到 140.4 億美元。

主要市場統計數據
基準年2024年 91.2億美元
預計2025年 97.7億美元
預測年份 2030 140.4億美元
複合年成長率（%） 7.46%

肺動脈高血壓(PAH) 是一種嚴重且複雜的心血管疾病，其特徵是肺動脈血壓升高，如果治療不當，會導致右心室勞損並最終導致心臟衰竭。這種疾病不僅帶來了重大的臨床挑戰，而且對全球醫療保健系統產生了重大影響。本報告對 PAH 市場進行了全面的介紹，並提供了對當前趨勢、轉型轉變、細分複雜性、區域差異以及推動治療策略創新的主要企業的專家分析。

診斷方法的最新進展，加上對 PAH 所涉及的分子路徑的深入了解，正在推動治療模式的快速發展。因此，人們越來越重視治療方法減輕症狀負擔同時延長預期壽命的治療方法。相關人員現在必須平衡功效、安全性和市場准入，同時也要應對不斷變化的監管和經濟狀況。

本摘要中概述的敘述不僅闡明了當前的市場狀況，而且還預測了由科學突破和行業專家之間的策略合作所推動的未來發展。該報告深入探討了由於更廣泛的經濟變化、技術進步和臨床實踐的轉變而導致的市場格局的演變，使其成為決策者和政策制定者的重要工具。該分析利用前沿研究和多學科見解，強調了基於證據的策略和數據主導的決策在應對多環芳烴帶來的挑戰中的關鍵作用。

改變肺動脈高血壓市場

近年來，肺動脈高血壓治療領域發生了重大變化。治療發展的創新和新技術的出現重新定義了治療通訊協定和市場預期。生物醫學研究的重要突破不僅提高了診斷的準確性，而且促進了改善患者預後和生活品質的標靶治療的創造。從傳統化療到生物技術解決方案的演變凸顯了精準醫療的更廣泛趨勢。

製藥公司和研究機構正在共同努力，利用分子生物學和基因分析在 PAH 治療中的潛力，提高現有治療的特異性和整體成功率。隨著這些新治療方法越來越普及，監管機構也同時適應新的模式，以確保安全標準跟上技術創新的快速步伐。

此外，數位健康平台、遠端醫療和先進監測設備的整合正在重新配置患者參與度和治療後追蹤通訊協定。這些技術進步使得即時監測患者生物標記成為可能，提供了十年前無法想像的個人化醫療保健解決方案。由此形成的由研究、技術和臨床應用組成的相互聯繫的生態系統將預示著以患者為中心的護理和市場活力的新時代的到來。正是這些因素的匯合不斷改變著競爭格局，挑戰著傳統觀念，並在對抗多環芳烴的鬥爭中釋放了前所未有的機會。

深入了解市場區隔

對 PAH 市場的詳細研究揭示了一個多方面的細分框架，為治療和分銷策略提供了清晰的指導。根據藥物類別，我們對治療方法進行了深入分析，包括構成目前治療方法，例如內皮素受體拮抗劑、磷酸二酯酶 5 抑制劑和類前列腺素。透過這種細分，可以全面評估每種藥物類別的臨床療效、安全性以及在更廣泛的治療領域中的定位。

同樣重要的分析涉及給藥途徑。這裡我們研究了靜脈注射、口服和皮下給藥方式的市場。給藥途徑的多樣性不僅影響患者的依從性和便利性，而且在決定整體治療結果方面也起著關鍵作用。此外，我們還將考慮按通路制定分銷策略，例如醫院藥局、網路藥局和零售藥局。這種分層提供了對可訪問性、供應鏈效率以及傳統和現代分銷網路之間不斷變化的動態的洞察。

最後，基於最終用戶人口統計的細分可以深入了解推動市場趨勢的需求區隔。分析的重點涵蓋學術和研究機構、診所和醫院等主要群體。這項全面的細分策略將使相關人員能夠識別市場機會、調整策略舉措並最佳化資源配置，以適應不斷變化的患者需求和不斷發展的醫療實踐。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 肺動脈高血壓盛行率及早期診斷的增加
      • 政府對肺動脈高血壓的支持和監管核准
    • 限制因素
      • 治療費用昂貴且保險覆蓋範圍有限
    • 機會
      • 肺動脈高血壓藥物研發投資與資金激增
      • 建立夥伴關係，共同開發和商業化肺動脈高血壓的藥物
    • 任務
      • 藥物研發中的高監管障礙和合規問題
  • 市場區隔分析
    • 藥物類別：對降低肺血管阻力的內皮素受體拮抗劑的需求不斷成長
    • 給藥途徑：靜脈注射越來越受到人們的青睞，因為它可以即時、可控制地輸送強效藥物。
    • 分銷：對線上藥局提高便利性和可近性的需求不斷成長
    • 最終用戶：醫院在複雜的 PAH 管理中的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章肺動脈高血壓市場（依藥物類別）

  • 內皮素受體拮抗劑
  • 磷酸二酯酶5抑制劑
  • 類前列腺素

第7章肺動脈高血壓市場（依給藥途徑）

  • 靜脈
  • 口服
  • 皮下

第8章肺動脈高血壓市場分佈

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第9章肺動脈高血壓市場（依最終用戶）

  • 學術研究所
  • 診所
  • 醫院

10.美洲肺動脈高血壓市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區肺動脈高血壓市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲肺動脈高血壓市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation
Product Code: MRR-030D347B0AD6

The Pulmonary Arterial Hypertension Market was valued at USD 9.12 billion in 2024 and is projected to grow to USD 9.77 billion in 2025, with a CAGR of 7.46%, reaching USD 14.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 9.12 billion
Estimated Year [2025] USD 9.77 billion
Forecast Year [2030] USD 14.04 billion
CAGR (%) 7.46%

Pulmonary arterial hypertension (PAH) is a formidable and complex cardiovascular condition characterized by elevated blood pressure in the pulmonary arteries, leading to right ventricular strain and eventual heart failure if inadequately managed. The condition not only poses significant clinical challenges but also drives substantial implications for healthcare systems globally. This report introduces an extensive exploration of the PAH market, providing expert analysis of current trends, transformational shifts, segmentation intricacies, regional variances, and the key players driving innovation in treatment strategies.

Recent advancements in diagnostic methodologies, coupled with a growing understanding of the molecular pathways involved in PAH, have catalyzed a rapid evolution in treatment paradigms. As a result, there is an increased emphasis on both established and emerging therapeutic approaches aimed at prolonging life expectancy while reducing symptom burden. Stakeholders are now compelled to balance considerations of efficacy, safety, and market access as they navigate an often evolving regulatory and economic landscape.

The narrative outlined in this summary not only delineates the state of the current market but also projects future developments fueled by scientific breakthroughs and strategic collaborations among industry experts. The report delves into how market conditions are being reshaped by broader economic changes, advancements in technology, and shifts in clinical practices, making it an indispensable tool for decision-makers and policy strategists alike. By leveraging cutting-edge research and cross-disciplinary insights, the analysis underscores the pivotal role of evidence-based strategies and data-driven decision-making in confronting the challenges posed by PAH.

Transformative Shifts in the Pulmonary Arterial Hypertension Landscape

The landscape of pulmonary arterial hypertension treatment has undergone significant transformation over recent years. Innovations in therapeutic development and the advent of new technologies have redefined treatment protocols and market expectations. Critical breakthroughs in biomedical research have not only improved diagnostic accuracy but also fostered the creation of targeted treatment modalities, which offer improved patient outcomes and quality of life. The evolution from conventional chemical therapies to biotechnologically driven solutions underscores a broader trend toward precision medicine.

Pharmaceutical companies and research institutions have collaboratively forged pathways to harness the potential of molecular biology and genetic profiling in PAH management, thereby enhancing both the specificity and overall success rates of available treatments. As these emerging therapies gain traction, regulatory agencies are simultaneously adapting to new paradigms, ensuring that safety standards keep pace with the rapid pace of innovation.

Moreover, the integration of digital health platforms, telemedicine, and advanced monitoring devices has reconfigured patient engagement and post-treatment follow-up protocols. These technological advancements enable real-time monitoring of patient biomarkers and offer personalized healthcare solutions that were unimaginable a decade ago. The resultant interconnected ecosystem of research, technology, and clinical application heralds a new era of patient-centered care and market dynamism. It is this confluence of factors that continues to fuel transformative shifts in the competitive landscape, challenging established norms and unlocking unprecedented opportunities in the fight against PAH.

Deep Dive into Market Segmentation Insights

A granular examination of the PAH market reveals a multifaceted segmentation framework that provides clarity on treatment and distribution strategies. The market is rigorously analyzed by drug class, with detailed insights into therapies involving Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Prostanoids, which form the cornerstone of current therapeutic regimens. This segmentation ensures a thorough evaluation of each drug category's clinical efficacy, safety profile, and positioning within the broader treatment landscape.

An equally critical dimension of analysis pertains to the route of administration. Here, the market is scrutinized under the modalities of Intravenous, Oral, and Subcutaneous delivery systems. The diversity in administration routes not only influences patient compliance and convenience but also plays a significant role in determining overall therapeutic outcomes. Furthermore, the distribution strategy is examined across channels that include Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. This stratification gives insight into accessibility, supply chain efficiencies, and the evolving dynamics between traditional and modern distribution networks.

Finally, the segmentation based on end-user demographics provides a window into the demand segments driving market trends. Analytical focus extends to key groups such as Academic and Research Institutions, Clinics, and Hospitals. This comprehensive segmentation strategy enables stakeholders to identify market opportunities, tailor strategic initiatives, and optimize resource allocation in alignment with shifting patient needs and evolving healthcare practices.

Based on Drug Class, market is studied across Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Prostanoids.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Based on End User, market is studied across Academic & Research Institutions, Clinics, and Hospitals.

Comprehensive Analysis of Global Regional Dynamics

An exhaustive regional analysis highlights how distinct economic, regulatory, and demographic factors shape the PAH market across various territories. The Americas continue to be a major hub for innovative treatment strategies, buoyed by robust healthcare infrastructure and significant investments in research and development. Clinicians and market participants in this region benefit from coordinated care models and a high degree of regulatory oversight, which collectively help in the swift adoption of advanced therapies.

In parallel, the combined region of Europe, Middle East & Africa is witnessing dynamic shifts catalyzed by progressive health policies and enhanced cross-border collaborations. The integration of research initiatives across academic institutions has paved the way for addressing regional disparities in treatment access and affordability. Furthermore, these regions are well known for their rigorous clinical testing environments that add a layer of robustness to market data.

Emerging as a focal point, the Asia-Pacific region brings its own set of unique challenges and opportunities, with rapid urbanization, evolving patient awareness, and a surge in investments directed at improving healthcare delivery systems. The increasing prevalence of PAH, concomitant with a growing middle class that demands higher quality healthcare, is gradually transforming market strategies. Together, these regions form a comprehensive mosaic of global trends, each contributing nuanced insights into the overall market dynamics and paving the way for future innovations in treatment and distribution strategies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Illuminating the Role of Key Market Players

The competitive landscape of the PAH market is defined by a mix of established titans and emerging innovators, each contributing uniquely to the sector's growth trajectory. Leading companies such as Alembic Pharmaceuticals Limited and AstraZeneca PLC are at the forefront of research-driven initiatives, spearheading clinical trials and pioneering novel therapeutic approaches. Their historical commitment to quality and innovation has been further reinforced by the vigorous participation of other global entities like Aurobindo Pharma Limited, Bayer AG, and Boehringer Ingelheim GmbH.

Visionary organizations including Cipla Limited, CMP Pharma, Inc., and Dr. Reddy's Laboratories Limited have significantly enhanced treatment accessibility through robust production networks and strategic market collaborations. In parallel, industry giants such as Eli Lilly and Company, Gilead Sciences, Inc., and GlaxoSmithKline PLC continue to redefine market benchmarks through groundbreaking research and transformative patient care protocols. The market's competitive fabric is further woven by the contributions of emerging players such as Gossamer Bio, Inc. and Gyre Therapeutics, Inc., who are relentlessly pursuing innovative treatments that promise to disrupt traditional paradigms.

The influence of well-established entities like Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., and Lupin Limited is evidenced by their extensive product portfolios and commitment to expanding global outreach. The formidable presence of multinational corporations including Merck KGaA, Novartis AG, and Pfizer, Inc., alongside strategic efforts by Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and United Therapeutics Corporation, ensures that expertise, reliability, and continuous improvement remain at the core of the market's evolution. This network of industry leaders not only fosters healthy competition but also promotes collaborative endeavors that drive the frontier of PAH treatment forward.

The report delves into recent significant developments in the Pulmonary Arterial Hypertension Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim GmbH, Cipla Limited, CMP Pharma, Inc., Dr. Reddy's Laboratories Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Gossamer Bio, Inc., Gyre Therapeutics, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and United Therapeutics Corporation. Strategic Recommendations for Industry Pioneers

In light of the multifaceted challenges and rapidly evolving market dynamics, industry leaders are urged to adopt a series of strategic recommendations designed to foster growth and sustainability. First, strengthening research and development initiatives remains paramount. Investment in cutting-edge technologies and fostering collaborations with academic institutions can accelerate the discovery of novel treatment modalities. Additionally, a keen focus on patient-centric care models is essential, particularly through the integration of digital health technologies that enhance real-time monitoring of disease progression. Stakeholders must also re-evaluate distribution channels, leveraging both traditional and digital marketplaces to ensure improved accessibility and streamlined logistics. Finally, ongoing risk assessment and adherence to evolving regulatory standards will be critical in maintaining market competitiveness and ensuring long-term success.

Conclusion: Charting the Future in Pulmonary Arterial Hypertension

The comprehensive analysis of the pulmonary arterial hypertension market underscores its remarkable dynamism and the potential for groundbreaking innovations in the near future. Amid an evolving therapeutic landscape marked by transformative research, diverse segmentation strategies, and robust regional variations, the market is poised to benefit from synergistic advancements that blend clinical insights with technological innovation. The interplay between established players and emerging innovators continues to redefine traditional paradigms, offering unparalleled opportunities to improve patient outcomes and expand treatment accessibility.

In summary, the insights presented in this report highlight pivotal trends, strategic challenges, and the collaborative spirit necessary to navigate a competitive market environment. As healthcare providers and decision-makers work together to harness these opportunities, the shared goal remains clear: to enhance the quality of life for patients suffering from PAH while simultaneously driving forward a new era of evidence-based, technology-driven care. The path forward is replete with challenges, but the potential to transform patient care and market dynamics stands as a testament to the resilience and capacity for innovation within the industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence and early diagnosis of pulmonary arterial hypertension
      • 5.1.1.2. Supportive government initiatives and regulatory approvals for pulmonary arterial hypertension
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limited insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging investments and funding for the advancement of pulmonary arterial hypertension drugs
      • 5.1.3.2. Partnership and collaborations to develop and commercialize pulmonary arterial hypertension drugs
    • 5.1.4. Challenges
      • 5.1.4.1. High regulatory hurdles and compliance issues in drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Rising need for endothelin receptor antagonists for reducing pulmonary vascular resistance
    • 5.2.2. Route Of Administration: Rising preference for intravenous administration for immediate and controlled delivery of potent medications
    • 5.2.3. Distribution: Growing demand for online pharmacies for enhanced convenience and broader accessibility
    • 5.2.4. End User: Rising significance of hospitals for complex PAH management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pulmonary Arterial Hypertension Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Endothelin Receptor Antagonists
  • 6.3. Phosphodiesterase-5 Inhibitors
  • 6.4. Prostanoids

7. Pulmonary Arterial Hypertension Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous

8. Pulmonary Arterial Hypertension Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Pulmonary Arterial Hypertension Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Clinics
  • 9.4. Hospitals

10. Americas Pulmonary Arterial Hypertension Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pulmonary Arterial Hypertension Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Corsair Pharma partners with InstantGMP to transform quality management for advanced transdermal pulmonary arterial hypertension therapy
    • 13.3.2. UK MHRA approves MSD's sotatercept therapy for pulmonary arterial hypertension
    • 13.3.3. XOMA Royalty Corporation strengthens its biotech pipeline with the acquisition of Pulmokine Inc.
    • 13.3.4. 35Pharma secures USD 53 million in Series C financing to accelerate clinical trials for HS135 in pulmonary hypertension
    • 13.3.5. BioCurate funds innovative research at Monash University to accelerate advanced treatment for pulmonary arterial hypertension
    • 13.3.6. Inhibikase Therapeutics secures USD 110 million in a private placement to fund its Phase 2b trial for IkT-001Pro
    • 13.3.7. NIH funds Cleveland Clinic-led trial evaluating novel therapeutics to reduce right-heart failure risk and mortality in pulmonary arterial hypertension patients
    • 13.3.8. Liquidia Corporation and Pharmosa Biopharm expand global strategic collaboration to enhance treatment options for PAH
    • 13.3.9. EC approval of Yuvanci marks a paradigm shift in pulmonary arterial hypertension treatment by offering Europe's first single-tablet combination therapy
    • 13.3.10. Liquidia Corporation secures tentative FDA approval for YUTREPIA in PAH and PH-ILD to enhance long-term market access and patient outcomes
    • 13.3.11. US FDA orphan drug designation for ZMA001 accelerates antibody development in phase 1a trials
    • 13.3.12. Inhibikase Therapeutics secures FDA new molecular entity designation for IkT-001Pro in pulmonary arterial hypertension
    • 13.3.13. Chiesi and Gossamer Bio collaborate to develop inhaled seralutinib to address pulmonary arterial hypertension
    • 13.3.14. Merck's FDA-approved Winrevair demonstrates significant clinical promise for pulmonary arterial hypertension
    • 13.3.15. The U.S. FDA grants approval for Johnson & Johnson's OPSYNVI to transform pulmonary arterial hypertension treatment
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Johnson & Johnson Services, Inc.
    • 13.4.2. Merck KGaA
    • 13.4.3. United Therapeutics Corporation
    • 13.4.4. Cipla Limited

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Bayer AG
  • 5. Boehringer Ingelheim GmbH
  • 6. Cipla Limited
  • 7. CMP Pharma, Inc.
  • 8. Dr. Reddy's Laboratories Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Gossamer Bio, Inc.
  • 13. Gyre Therapeutics, Inc.
  • 14. Hikma Pharmaceuticals PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. Merck KGaA
  • 18. Novartis AG
  • 19. Pfizer, Inc.
  • 20. Sun Pharmaceutical Industries Limited
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. Torrent Pharmaceuticals Limited
  • 23. United Therapeutics Corporation

LIST OF FIGURES

  • FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-CURRENCY
  • FIGURE 2. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-LANGUAGE
  • FIGURE 3. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
  • FIGURE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PULMONARY ARTERIAL HYPERTENSION MARKET DYNAMICS
  • TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 192. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024